Lexicon Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview

Lexicon Pharmaceuticals

03/11/2023 11:07

* Lexicon Pharmaceuticals Inc  LXRX.OQ   LXRX.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The The Woodlands Texas-based  company is expected to
report  a
5,182.1% increase in revenue to $2.06 million from $39 thousand
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Lexicon
Pharmaceuticals
Inc is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lexicon
Pharmaceuticals Inc is $5​, above​ its last closing price
of $1.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.17       -0.17      -0.22     Missed  -25.9
 Mar. 31 2023  -0.18       -0.18      -0.17     Beat    5.2
 Dec. 31 2022  -0.14       -0.13      -0.16     Missed  -19.4​
 Sep. 30 2022  -0.14       -0.14      -0.13     Beat    6.7
 ​​Jun.        -0.16       -0.16      -0.16     Met     -1.7
 30 2022                                                
 Mar. 31 2022  -0.17       -0.16      -0.16     Met     2.8​
 Dec. 31 2021  -0.18       -0.18      -0.17     Beat    6.9
 Sep. 30 2021  -0.18       -0.18      -0.16     Beat    9.6
 This summary was machine generated November 3 at 11:06 GMT.  All
figures in US dollars  unless otherwise stated